Plasma level of platelet-derived microparticles is associated with coronary heart disease risk score in healthy men

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 4, 2010, Pages 342-349

  Ueba, Tetsuya ^a   Nomura, Shosaku ^a   Inami, Norihito ^b   Nishikawa, Tomofumi ^a   Kajiwara, Motohiro ^a   Iwata, Ryoichi ^a   Yamashita, Kohsuke ^a  

^a Kishiwada City Hospital   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherothrombosis; Framingham coronary heart disease risk score; High sensitivity CRP; Platelet derived microparticle

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; GLYCOPROTEIN IB ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISCHEMIC HEART DISEASE; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PLATELET MICROPARTICLE; PREDICTION; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; WAIST CIRCUMFERENCE;

EID: 77953511829     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.2964     Document Type: Article

References (48)

1. Miyazaki Y, Nomura S, Miyake T, Kagawa H, Kitada C, Taniguchi H, Komiyama Y, Fujimura Y, Ikeda Y, Fuku-hara S: High shear stress can initiate both platelet aggregation and shedding of procoagulant-containing microparticles. Blood, 1996; 88: 3456-3464
2. Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM: Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood, 2006; 107: 3537-3545
3. Ray DM, Spinelli SL, Pollock SJ, Murant TI, O'Brien JJ, Blumberg N, Francis CW, Taubman MB, Phipps RP: Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost, 2008; 99: 86-95
4. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP: Platelets as predictors of vascular risk: Is there a practical index of platelet activity? Clin Appl Thromb Hemost, 2003; 9: 177-190
5. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, Ataullakhanov FI: Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost, 2007; 97: 425-434
6. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 1998; 391: 591-594.
7. Nomura S: Function and clinical significance of platelet derived microparticles. Int J Hematol, 2001; 74: 397-404.
8. Hodis HN: Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation, 1999; 99: 2852-2854.
9. Yamazaki M, Uchiyama S, Xiong Y, Nakano T, Nakamura T, Iwata M: Effect of remnant-like particles on shear-induced platelet activation and its inhibition by antiplatelet agents. Thromb Res, 2005; 115: 211-218
10. Nomura S, Suzuki M, Katsura K, Xie GL, Miyazaki Y, Miyake T, Kido H, Kagawa H, Fukuhara S: Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis, 1995; 116: 235-240
11. Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y: Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost, 2003; 89: 506-512
12. Namba M, Tanaka A, Shimada K, Ozeki Y, Uehata S, Sakamoto T, Nishida Y, Nomura S, Yoshikawa J: Circulating platelet-derived microparticles are associated with ath erothrombotic events: A marker for vulnerable blood. Arterioscler Thromb Vasc Biol, 2007; 27: 255-256
13. van der Zee PM, Biró E, Ko Y, de Winter RJ, Hack CE, Sturk A, Nieuwland R: P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem, 2006; 52: 657-664
14. Tan KT, Tayebjee MH, Lim HS, Lip GY: Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med, 2005; 22: 1657-1662
15. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY: Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers. Ann Med, 2005; 37: 61-66
16. Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD: Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets, 2005; 16: 368-371
17. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL: Platelet dysfunction in type 2 diabetes. Diabetes Care, 2001; 24: 1476-1485
18. Diamant M, Tushuizen ME, Sturk A, Nieuwland R: Cellular microparticles: New players in the field of vascular disease? Eur J Clin Invest, 2004; 34: 392-401
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497
20. Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med, 2006; 119: 812-819.
21. Devaraj S, Rosenson RS, Jialal I: Metabolic syndrome: An appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Amer, 2004; 33: 431-453
22. Wiberg B, Sundström J, Arnlöv J, Terént A, Vessby B, Zethelius B, Lind L: Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: A community-based study with long-term follow-up. Stroke, 2006; 37: 2898-2903
23. Satoh A, Adachi H, Tsuruta M, Hirai Y, Hiratsuka A, Enomoto M, Furuki K, Hino A, Takeuchi T, Imaizumi T: High plasma level of remnant-like particle cholesterol in the metabolic syndrome. Diabetes Care, 2005; 28: 2514-2518
24. Ishikawa S, Kayaba K, Gotoh T, Nakamura Y, Kajii E: Metabolic syndrome and C-reactive protein in the general population: JMS Cohort Study. Circ J, 2007; 71: 26-31
25. Ueba T, Haze T, Sugiyama M, Higuchi M, Asayama H, Karitani Y, Nishikawa T, Yamashita K, Nagami S, Nakayama T, Kanatani K, Nomura S: Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syn- drome. Thromb Haemost, 2008; 100: 280-285
26. Daly CA, Hildebrandt P, Bertrand M, Ferrari R, Remme W, Simoons M, Fox KM; EUROPA investigators: Adverse prognosis associated with the metabolic syndrome in the established coronary artery diwsease: data from the EUROPA trial Heart, 2007; 93: 1406-1411
27. Diamant M, Tushuizen ME: The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD. Curr Diab Rep, 2006; 6: 279-286.
28. Lee YJ, Jy W, Horstman LL, Janania J, Reyes Y, Kelley RE, Ahn YS: Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res, 1993; 72: 295-304
29. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Sil-bershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97: 1837-1847
30. Osumi K, Ozeki Y, Saito S, Nagamura Y, Ito H, Kimura Y, Ogura H, Nomura S: Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost, 2001; 85: 326-330
31. Nomura S, Kanazawa S, Fukuhara S: Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens, 2002; 16: 539-547
32. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T: Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. Thromb Res, 2005; 115: 277-285.
33. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T: Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thromboly- sis, 2004; 18: 177-185
34. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005; 112: 2735-2752
35. Kanatani K, Nomura S: A method for measurement of platelet-derived microparticles. Jpn J Thromb Hemostasis, 2007; 18: 653-659
36. Whicher J, Rifai N, Biasucci LM: Markers of the acute phase response in cardiovascular disease. An update. Clin Chem Lab Med, 2001; 39: 1054-1064
37. Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J: High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis, 2001; 158: 277-287.
38. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C: Platelet microparticles: A transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol, 2005; 25: 1512-1518
39. Marutsuka K, Hatakeyama K, Yamashita A, Asada Y: Role of thrombogenic factors in the development of atherosclerosis. J Atheroscler Thromb, 2005; 12: 1-8
40. Holme PA, Orvim U, Hamers MJ, Solum NO, Brosstad FR, Barstad RM, Sakariassen KS: Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with severe stenosis. Arterio- scler Thromb Vasc Biol, 1997; 17: 646-653
41. Michibayashi T: Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways. J Atheroscler Thromb, 2005; 12: 154-162
42. Sato Y, Fujii S, Imagawa S, Ohmura K, Ohmura Y, Andoh Y, Dong J, Ishimori N, Furumoto T, Tsutsui H: Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J Atheroscler Thromb, 2007; 14: 31-35.
43. Weber A, Köppen HO, Schrör K: Platelet-derived microparticles stimulate coronary artery smooth muscle cell mitogenesis by a PDGF-independent mechanism. Thromb Res, 2000; 98: 461-466
44. Shoji T, Koyama H, Fukumoto S, Maeno T, Yokoyama H, Shinohara K, Emoto M, Shoji T, Inaba M, Nishizawa Y: Platelet-monocyte aggregates are independently associated with occurrence of carotid plaques in type 2 diabetic patients. J Atheroscler Thromb, 2005; 12: 344-352.
45. Chironi G, Simon A, Hugel B, Del Pino M, Gariepy J, Freyssinet JM, Tedgui A: Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol, 2006; 26: 2775-2780
46. Arteaga RB, Chirinos JA, Soriano AO, Jy W, Horstman L, Jimenez JJ, Mendez A, Ferreira A, de Marchena E, Ahn YS: Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol, 2006; 98: 70-74
47. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, de Marchena E, Ahn YS: High levels of circulating endothelial microparticles in patients with acute coronary syndrome. Am Heart J, 2003; 145: 962-970
48. Diehl P, Nagy F, Sossong V, Helbing T, Beyersdorf F, Olschewski M, Bode C, Moser M: Increased levels of circulating microparticles in patients with severe aortic valve stenosis. Thromb Haemost, 2008; 99: 711-719.